第二代测序技术在肿瘤诊疗中的应用及其价值与风险

doi:10.3969/j.issn.1673-8640.2017.04.001

检验医学 ›› 2017, Vol. 32 ›› Issue (4): 245-249.DOI: 10.3969/j.issn.1673-8640.2017.04.001

• 二代测序技术的临床应用专题 • 下一篇

第二代测序技术在肿瘤诊疗中的应用及其价值与风险

樊绮诗¹, 吴蓓颖²

1.上海交通大学医学院附属瑞金医院北院检验科,上海 201801
2.上海交通大学医学院附属瑞金医院检验科,上海 200025

收稿日期:2016-08-21 出版日期:2017-04-20 发布日期:2017-05-01
作者简介:null
作者简介：樊绮诗,女,1953年生,博士,研究员,主要从事分子生物学和临床检验诊断学相关研究。

Value and risk of next generation sequencing in the diagnosis and treatment of cancer

FAN Qishi¹, WU Beiying²

1. Department of Clinical Laboratory,North Campus,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 201801,China
2. Department of Clinical Laboratory,Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200025,China

Received:2016-08-21 Online:2017-04-20 Published:2017-05-01

摘要/Abstract

摘要：

测序技术从第1代发展至今的第4代,读长从长到短,又再由短至长。每一次技术进步都有力地促进了生命科学和临床医学研究的发展。其中高通量测序又称下一代测序（next generation sequencing,NGS）技术即二代测序技术因其通量大、精确度高且信息量丰富,不同的测序平台在通量、读长、准确度、速度和成本方面各具优势,在基因组从头测序、重测序、转录组及表观遗传学研究中发挥了重要作用。近年来,NGS的数据产出一直呈现出指数增长的趋势,并逐渐应用于个性化医疗和遗传诊断等临床服务。NGS在临床肿瘤的研究与检测中也显示出巨大的市场价值,但是在此背后却同时存在着一定程度的风险,不得不引起我们的重视和警惕。

关键词: 高通量测序, 肿瘤

Abstract:

Sequencing technology has been developed from the 1st generation to the 4th one,and the length of reads is from long to short and from short to long again. Its progress has promoted the development of life science and clinical medical research. Next generation sequencing （NGS） technology has high flux,high accuracy and huge quantity of information. Different sequencing platforms have their own advantages in flux,length of reads,accuracy,speed and cost. They play important roles in de novo genome sequencing,resequencing,transcriptome and apparent genetics. In recent years,the datum output of NGS shows the trend of exponential growth,and has been gradually applied to clinical services,such as personalized medicine and genetic diagnosis. NGS in clinical oncology research and determination also shows a huge market value,but at the same time it hides certain degree of risk,which should be paid great attention and vigilance.

Key words: Next generation sequencing, Cancer

中图分类号:

R393

樊绮诗, 吴蓓颖. 第二代测序技术在肿瘤诊疗中的应用及其价值与风险[J]. 检验医学, 2017, 32(4): 245-249.

FAN Qishi, WU Beiying. Value and risk of next generation sequencing in the diagnosis and treatment of cancer[J]. Laboratory Medicine, 2017, 32(4): 245-249.

参考文献 16

[1]	LEE J J,SHOLL L M,Lindeman N I,et al.Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naive patient melanomas[J]. Clin Epigenetics,2015,7:59.
[2]	EKBLOM R,WOLF J B.A field guide to whole-genome sequencing,assembly and annotation[J]. Evol Appl,2014,7(9):1026-1042.
[3]	GRIEBEL T,ZACHER B,RIBECA P,et al.Modelling and simulating generic RNA-Seq experiments with the flux simulator[J]. Nucleic Acids Res,2012,40(20):10073-10083.
[4]	GAHL W A,MARKELLO T C,TORO C,et al.The national institutes of health undiagnosed diseases program:insights into rare diseases[J]. Genet Med,2012,14(1):51-59.
[5]	MA L,SHAN Y,BAI R,et al. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia [J]. Sci Transl Med,2014,6(252):252ra121.
[6]	FOUNTZILAS G,GIANNOULATOU E,ALEXOPOULOU Z,et al.TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting[J]. Oncotarget,2016,7(22):32731-32753.
[7]	KOBAYASHI Y,MITSUDOMI T.Not all epidermal growth factor receptor mutations in lung cancer are created equal:perspectives for individualized treatment strategy[J]. Cancer Sci,2016,107(9):1179-1186.
[8]	XING M.Molecular pathogenesis and mechanisms of thyroid cancer[J]. Nat Rev Cancer,2013,13(3):184-199.
[9]	ROTHSCHILD S I.Targeted therapies in non-small cell lung cancer-beyond EGFR and ALK[J]. Cancers(Basel),2015,7(2):930-949.
[10]	AZIZ N,ZHAO Q,BRY L,et al.College of American Pathologists' laboratory standards for next-generation sequencing clinical tests[J]. Arch Pathol Lab Med,2015,139(4):481-493.
[11]	BENTLEY D R,BALASUBRAMANIAN S,SWERDLOW H P,et al.Accurate whole human genome sequencing using reversible terminator chemistry[J]. Nature,2008,456(7218):53-59.
[12]	LEY T J,MARDIS E R,DING L,et al.DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome[J]. Nature,2008,456(7218):66-72.
[13]	SARIN S,PRABHU S,O'MEARA M M,et al. Caenorhabditis elegans mutant allele identification by whole-genome sequencing[J]. Nat Methods,2008,5(10):865-867.
[14]	DRMANAC R,SPARKS A B,CALLOW M J,et al.Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays[J]. Science,2010,327(5961):78-81.
[15]	VALOUEV A,ICHIKAWA J,TONTHAT T,et al.A high-resolution,nucleosome position map of C. elegans reveals a lack of universal sequence-dictated positioning[J]. Genome Res,2008,18(7):1051-1063.
[16]	LOMAN N J,MISRA R V,DALLMAN T J,et al.Performance comparison of benchtop high-throughput sequencing platforms[J]. Nat Biotechnol,2012,30(5):434-439.

第二代测序技术在肿瘤诊疗中的应用及其价值与风险

Value and risk of next generation sequencing in the diagnosis and treatment of cancer

RichHTML

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献 16

相关文章 15

编辑推荐

Metrics

[1]	周韵斓, 沈立松. 液体活检标志物在非小细胞肺癌中的临床应用和挑战[J]. 检验医学, 2023, 38(9): 807-811.
[2]	王杨淑怡, 叶威, 林志豪, 黄约诺, 方涛, 董晓亭. 肺腺癌焦亡相关特征模型的构建和验证[J]. 检验医学, 2023, 38(9): 833-841.
[3]	彭伟, 李运改, 许静, 刘华, 杨翠霞, 沈云岳. 血清炎症因子联合PSA、f-PSA可辅助诊断前列腺癌[J]. 检验医学, 2023, 38(9): 849-854.
[4]	卫明珠, 潘继文, 罗锐, 陈俊辉. 凝血4项和肿瘤标志物对乙型肝炎相关肝癌的辅助诊断价值[J]. 检验医学, 2023, 38(9): 901-904.
[5]	丁肖媛, 戴劲盛, 焦荣红, 马素丽, 朱海峰, 吴梦雅, 车艳然, 张蕾. 肥胖/超重对哮喘发作期患儿Th1/Th2和Th17/Treg细胞因子的影响[J]. 检验医学, 2023, 38(8): 748-752.
[6]	王腾飞, 陈珊, 安和兵, 周蕾. 急性白血病患者外周血lncRNA CRNDE、miR-384表达及其临床意义[J]. 检验医学, 2023, 38(7): 686-691.
[7]	赵婧, 王佩, 卢丹丹, 齐丹丹, 李轩. 出血性脑卒中患者血清miR-4443、TRAF4相对表达量变化的临床意义[J]. 检验医学, 2023, 38(5): 413-418.
[8]	高锋. 新型肿瘤标志物的临床应用——前景与挑战[J]. 检验医学, 2023, 38(4): 303-306.
[9]	刘瑞丽, 李兰军, 贾旻蕾, 王一惠, 郝维纳. 胃癌组织miR-7-5p、NOVA2表达与患者临床预后的相关性[J]. 检验医学, 2023, 38(4): 325-329.
[10]	宋世伟, 李景武, 林韬, 刘泽宇, 王志强, 孙卫东. GPNMB与非小细胞肺癌患者肿瘤免疫浸润和预后的相关性[J]. 检验医学, 2023, 38(4): 347-351.
[11]	陈哲, 张灵, 刘洁, 王霞, 张斌, 高炳华. 血清miR-326与治疗相关性血液系统恶性肿瘤患者化疗敏感性和预后的关系[J]. 检验医学, 2023, 38(3): 251-256.
[12]	吴炯, 胡嘉华, 施美芳, 刘涛, 戴洁, 卢忻怡, 邹政. 前列腺癌生物标志物研究进展[J]. 检验医学, 2023, 38(2): 190-195.
[13]	池锐彬, 周卉芬, 叶铨秋, 李超锋. NGS快速诊断疑难鹦鹉热衣原体重症肺炎合并脓毒症休克1例报道[J]. 检验医学, 2023, 38(12): 1211-1212.
[14]	陈馨宁, 黄斐, 姜惠琴, 沈敏娜, 潘柏申, 王蓓丽, 郭玮. 非小细胞肺癌患者血浆EGFR基因c.2572_2573delinsAG位点突变1例报道[J]. 检验医学, 2023, 38(10): 1003-1005.
[15]	钱琳玉, 梁卫芳, 唐思晨. 妊娠糖尿病患者NLRP3、CTRP6和IL-1β检测的临床意义[J]. 检验医学, 2023, 38(10): 936-940.